Contemporary grading for prostate cancer

Implications for patient care

Fadi Brimo, Rodolfo Montironi, Lars Egevad, Andreas Erbersdobler, Daniel W. Lin, Joel B. Nelson, Mark A. Rubin, Theo Van Der Kwast, Mahul Amin, Jonathan I. Epstein

Research output: Contribution to journalReview article

53 Citations (Scopus)

Abstract

Context: The Gleason grading system is one of the most powerful predictors of outcome in prostate cancer and a cornerstone in counseling and treating patients. Since its inception, it has undergone several modifications triggered by a change in clinical practice and a better understanding of the cancer's histologic spectrum and variants and their prognostic significance. Objective: To provide an overview of the implementation and the impact of the Gleason system as a predictive and prognostic tool in all available treatment modalities, and to compare the original and modified Gleason systems in major pathologic and clinical outcome data sets. Evidence acquisition: A comprehensive nonsystematic Medline search was performed using multiple Medical Subject Headings such as Gleason, modified, system, outcome, biopsy, prostatectomy, recurrence, prognosis, radiotherapy, and focal therapy, with restriction to the English language and a preference for publications within the last 10 yr. All Gleason grade-related studies in the last 3 yr were reviewed. For studies before this date, we relied on prior culling of the literature for various recent books, chapters, and original articles on this topic. Evidence synthesis: Using the modified grading system resulted in disease upgrading with more cancers assigned a Gleason score ≥7 than in the past. It also resulted in a more homogeneous Gleason score 6, which has an excellent prognosis when the disease is organ confined. The vast majority of studies using both systems showed that Gleason grading of adenocarcinomas on needle biopsies and radical prostatectomies was strongly associated with pathologic stage, status of surgical margins, metastatic disease, biochemical recurrence, and cancer-specific survival, with the modified system outperforming the original one in some large series. A description of the continuous incorporation of this parameter in the clinical decision making for treating prostate cancer using all currently used treatment modalities is presented, and the findings of studies before and after the inception of the modified grading system, if available, are compared. The proposed contemporary grading prognostic categories are 3 + 3, 3 + 4, 4 + 3, 8, and 9-10. Conclusions: The Gleason score is one of the most critical predictive factors of prostate cancer regardless of the therapy used. Modernization of the Gleason grading system has resulted in a more accurate grading system for radical prostatectomy (RP) but has complicated the comparison of data before and after the updating. A better prognostication with the updated Gleason grading system for patients treated with modalities other than surgery can only be postulated at this time because there are limited conflicting data on radiation and no studies on other treatment modalities. Its greatest impact is the uniformly excellent prognosis associated with Gleason score 6 in RPs.

Original languageEnglish (US)
Pages (from-to)892-901
Number of pages10
JournalEuropean Urology
Volume63
Issue number5
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Patient Care
Prostatectomy
Medical Subject Headings
Therapeutics
Recurrence
Neoplasms
Needle Biopsy
Social Change
Publications
Counseling
Adenocarcinoma
Language
Radiotherapy
Radiation
Biopsy
Survival

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Brimo, F., Montironi, R., Egevad, L., Erbersdobler, A., Lin, D. W., Nelson, J. B., ... Epstein, J. I. (2013). Contemporary grading for prostate cancer: Implications for patient care. European Urology, 63(5), 892-901. https://doi.org/10.1016/j.eururo.2012.10.015

Contemporary grading for prostate cancer : Implications for patient care. / Brimo, Fadi; Montironi, Rodolfo; Egevad, Lars; Erbersdobler, Andreas; Lin, Daniel W.; Nelson, Joel B.; Rubin, Mark A.; Van Der Kwast, Theo; Amin, Mahul; Epstein, Jonathan I.

In: European Urology, Vol. 63, No. 5, 01.01.2013, p. 892-901.

Research output: Contribution to journalReview article

Brimo, F, Montironi, R, Egevad, L, Erbersdobler, A, Lin, DW, Nelson, JB, Rubin, MA, Van Der Kwast, T, Amin, M & Epstein, JI 2013, 'Contemporary grading for prostate cancer: Implications for patient care', European Urology, vol. 63, no. 5, pp. 892-901. https://doi.org/10.1016/j.eururo.2012.10.015
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB et al. Contemporary grading for prostate cancer: Implications for patient care. European Urology. 2013 Jan 1;63(5):892-901. https://doi.org/10.1016/j.eururo.2012.10.015
Brimo, Fadi ; Montironi, Rodolfo ; Egevad, Lars ; Erbersdobler, Andreas ; Lin, Daniel W. ; Nelson, Joel B. ; Rubin, Mark A. ; Van Der Kwast, Theo ; Amin, Mahul ; Epstein, Jonathan I. / Contemporary grading for prostate cancer : Implications for patient care. In: European Urology. 2013 ; Vol. 63, No. 5. pp. 892-901.
@article{88696591e11041c89ffdf63342327817,
title = "Contemporary grading for prostate cancer: Implications for patient care",
abstract = "Context: The Gleason grading system is one of the most powerful predictors of outcome in prostate cancer and a cornerstone in counseling and treating patients. Since its inception, it has undergone several modifications triggered by a change in clinical practice and a better understanding of the cancer's histologic spectrum and variants and their prognostic significance. Objective: To provide an overview of the implementation and the impact of the Gleason system as a predictive and prognostic tool in all available treatment modalities, and to compare the original and modified Gleason systems in major pathologic and clinical outcome data sets. Evidence acquisition: A comprehensive nonsystematic Medline search was performed using multiple Medical Subject Headings such as Gleason, modified, system, outcome, biopsy, prostatectomy, recurrence, prognosis, radiotherapy, and focal therapy, with restriction to the English language and a preference for publications within the last 10 yr. All Gleason grade-related studies in the last 3 yr were reviewed. For studies before this date, we relied on prior culling of the literature for various recent books, chapters, and original articles on this topic. Evidence synthesis: Using the modified grading system resulted in disease upgrading with more cancers assigned a Gleason score ≥7 than in the past. It also resulted in a more homogeneous Gleason score 6, which has an excellent prognosis when the disease is organ confined. The vast majority of studies using both systems showed that Gleason grading of adenocarcinomas on needle biopsies and radical prostatectomies was strongly associated with pathologic stage, status of surgical margins, metastatic disease, biochemical recurrence, and cancer-specific survival, with the modified system outperforming the original one in some large series. A description of the continuous incorporation of this parameter in the clinical decision making for treating prostate cancer using all currently used treatment modalities is presented, and the findings of studies before and after the inception of the modified grading system, if available, are compared. The proposed contemporary grading prognostic categories are 3 + 3, 3 + 4, 4 + 3, 8, and 9-10. Conclusions: The Gleason score is one of the most critical predictive factors of prostate cancer regardless of the therapy used. Modernization of the Gleason grading system has resulted in a more accurate grading system for radical prostatectomy (RP) but has complicated the comparison of data before and after the updating. A better prognostication with the updated Gleason grading system for patients treated with modalities other than surgery can only be postulated at this time because there are limited conflicting data on radiation and no studies on other treatment modalities. Its greatest impact is the uniformly excellent prognosis associated with Gleason score 6 in RPs.",
author = "Fadi Brimo and Rodolfo Montironi and Lars Egevad and Andreas Erbersdobler and Lin, {Daniel W.} and Nelson, {Joel B.} and Rubin, {Mark A.} and {Van Der Kwast}, Theo and Mahul Amin and Epstein, {Jonathan I.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2012.10.015",
language = "English (US)",
volume = "63",
pages = "892--901",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Contemporary grading for prostate cancer

T2 - Implications for patient care

AU - Brimo, Fadi

AU - Montironi, Rodolfo

AU - Egevad, Lars

AU - Erbersdobler, Andreas

AU - Lin, Daniel W.

AU - Nelson, Joel B.

AU - Rubin, Mark A.

AU - Van Der Kwast, Theo

AU - Amin, Mahul

AU - Epstein, Jonathan I.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Context: The Gleason grading system is one of the most powerful predictors of outcome in prostate cancer and a cornerstone in counseling and treating patients. Since its inception, it has undergone several modifications triggered by a change in clinical practice and a better understanding of the cancer's histologic spectrum and variants and their prognostic significance. Objective: To provide an overview of the implementation and the impact of the Gleason system as a predictive and prognostic tool in all available treatment modalities, and to compare the original and modified Gleason systems in major pathologic and clinical outcome data sets. Evidence acquisition: A comprehensive nonsystematic Medline search was performed using multiple Medical Subject Headings such as Gleason, modified, system, outcome, biopsy, prostatectomy, recurrence, prognosis, radiotherapy, and focal therapy, with restriction to the English language and a preference for publications within the last 10 yr. All Gleason grade-related studies in the last 3 yr were reviewed. For studies before this date, we relied on prior culling of the literature for various recent books, chapters, and original articles on this topic. Evidence synthesis: Using the modified grading system resulted in disease upgrading with more cancers assigned a Gleason score ≥7 than in the past. It also resulted in a more homogeneous Gleason score 6, which has an excellent prognosis when the disease is organ confined. The vast majority of studies using both systems showed that Gleason grading of adenocarcinomas on needle biopsies and radical prostatectomies was strongly associated with pathologic stage, status of surgical margins, metastatic disease, biochemical recurrence, and cancer-specific survival, with the modified system outperforming the original one in some large series. A description of the continuous incorporation of this parameter in the clinical decision making for treating prostate cancer using all currently used treatment modalities is presented, and the findings of studies before and after the inception of the modified grading system, if available, are compared. The proposed contemporary grading prognostic categories are 3 + 3, 3 + 4, 4 + 3, 8, and 9-10. Conclusions: The Gleason score is one of the most critical predictive factors of prostate cancer regardless of the therapy used. Modernization of the Gleason grading system has resulted in a more accurate grading system for radical prostatectomy (RP) but has complicated the comparison of data before and after the updating. A better prognostication with the updated Gleason grading system for patients treated with modalities other than surgery can only be postulated at this time because there are limited conflicting data on radiation and no studies on other treatment modalities. Its greatest impact is the uniformly excellent prognosis associated with Gleason score 6 in RPs.

AB - Context: The Gleason grading system is one of the most powerful predictors of outcome in prostate cancer and a cornerstone in counseling and treating patients. Since its inception, it has undergone several modifications triggered by a change in clinical practice and a better understanding of the cancer's histologic spectrum and variants and their prognostic significance. Objective: To provide an overview of the implementation and the impact of the Gleason system as a predictive and prognostic tool in all available treatment modalities, and to compare the original and modified Gleason systems in major pathologic and clinical outcome data sets. Evidence acquisition: A comprehensive nonsystematic Medline search was performed using multiple Medical Subject Headings such as Gleason, modified, system, outcome, biopsy, prostatectomy, recurrence, prognosis, radiotherapy, and focal therapy, with restriction to the English language and a preference for publications within the last 10 yr. All Gleason grade-related studies in the last 3 yr were reviewed. For studies before this date, we relied on prior culling of the literature for various recent books, chapters, and original articles on this topic. Evidence synthesis: Using the modified grading system resulted in disease upgrading with more cancers assigned a Gleason score ≥7 than in the past. It also resulted in a more homogeneous Gleason score 6, which has an excellent prognosis when the disease is organ confined. The vast majority of studies using both systems showed that Gleason grading of adenocarcinomas on needle biopsies and radical prostatectomies was strongly associated with pathologic stage, status of surgical margins, metastatic disease, biochemical recurrence, and cancer-specific survival, with the modified system outperforming the original one in some large series. A description of the continuous incorporation of this parameter in the clinical decision making for treating prostate cancer using all currently used treatment modalities is presented, and the findings of studies before and after the inception of the modified grading system, if available, are compared. The proposed contemporary grading prognostic categories are 3 + 3, 3 + 4, 4 + 3, 8, and 9-10. Conclusions: The Gleason score is one of the most critical predictive factors of prostate cancer regardless of the therapy used. Modernization of the Gleason grading system has resulted in a more accurate grading system for radical prostatectomy (RP) but has complicated the comparison of data before and after the updating. A better prognostication with the updated Gleason grading system for patients treated with modalities other than surgery can only be postulated at this time because there are limited conflicting data on radiation and no studies on other treatment modalities. Its greatest impact is the uniformly excellent prognosis associated with Gleason score 6 in RPs.

UR - http://www.scopus.com/inward/record.url?scp=84876057180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876057180&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.10.015

DO - 10.1016/j.eururo.2012.10.015

M3 - Review article

VL - 63

SP - 892

EP - 901

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -